Compare VNDA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNDA | DCTH |
|---|---|---|
| Founded | 2002 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.3M | 363.5M |
| IPO Year | 2005 | 2015 |
| Metric | VNDA | DCTH |
|---|---|---|
| Price | $6.00 | $10.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $14.90 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.1M | 388.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $216,105,000.00 | N/A |
| Revenue This Year | $21.35 | $24.54 |
| Revenue Next Year | $37.40 | $33.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $4.14 | $8.12 |
| 52 Week High | $9.91 | $18.19 |
| Indicator | VNDA | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.15 | 49.81 |
| Support Level | $5.73 | $10.22 |
| Resistance Level | $7.76 | $11.14 |
| Average True Range (ATR) | 0.30 | 0.55 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 2.83 | 33.72 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.